SG Americas Securities
OREX

SG Americas Securities’s Orexigen Therapeutics, Inc. OREX Stock Holding History

SG Americas Securities’s Portfolio OREX Stock Details OREX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-5,000
Closed -$2K – 3573
2014
Q3 		$2K Hold
5,000
– – ﹤0.01% 2607
2014
Q2 		$2K Buy
+5,000
New +$291K ﹤0.01% 2489

Other funds holding OREX

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
SC
Samlyn Capital New York $5.86B AUM 36.3% 1-Year Est. Return
FCMI
Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
FCMI
Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

SG Americas Securities's OREX Position: Q3 2016 in Review

SG Americas Securities sold out of Orexigen Therapeutics, Inc. (OREX) in Q3 2016, closing a stake of 4,833 shares — an estimated $21K sold.

SG Americas Securities first reported a position in OREX in Q3 2013 and held it in 5 quarters. The position peaked at $142K in Q3 2013. 55 funds tracked by Wall St. Rank hold OREX as of Q3 2016.

  • SG Americas Securities reported no remaining Orexigen Therapeutics, Inc. position as of Q3 2016 after selling out during the quarter.
  • SG Americas Securities sold 4,833 Orexigen Therapeutics, Inc. shares in Q3 2016, an estimated $21K.
  • SG Americas Securities first reported a position in Orexigen Therapeutics, Inc. in Q3 2013 and held it in 5 quarters.
  • SG Americas Securities's Orexigen Therapeutics, Inc. position peaked at $142K in Q3 2013.
  • 55 funds tracked by Wall St. Rank held Orexigen Therapeutics, Inc. as of Q3 2016.

Based on SG Americas Securities's 13F filing for Q3 2016, filed 8 Nov 2016.